These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 2173113)

  • 1. Cytomegalovirus immunoglobulins in the prevention and treatment of cytomegalovirus disease.
    Snydman DR
    Rev Infect Dis; 1990; 12 Suppl 7():S839-48. PubMed ID: 2173113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of combined prophylaxis of cytomegalovirus hyperimmune globulin plus ganciclovir versus cytomegalovirus hyperimmune globulin alone in high-risk heart transplant recipients.
    Bonaros NE; Kocher A; Dunkler D; Grimm M; Zuckermann A; Ankersmit J; Ehrlich M; Wolner E; Laufer G
    Transplantation; 2004 Mar; 77(6):890-7. PubMed ID: 15077033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prophylaxis of CMV infection in bone marrow transplant recipients by hyperimmune CMV gamma-globulin.
    Condie RM; O'Reilly RJ
    Dev Biol Stand; 1982; 52():501-13. PubMed ID: 6299859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Valganciclovir (VGCV) followed by cytomegalovirus (CMV) hyperimmune globulin compared to VGCV for 200 days in abdominal organ transplant recipients at high risk for CMV infection: A prospective, randomized pilot study.
    Fleming JN; Taber DJ; Weimert NA; Nadig S; McGillicuddy JW; Bratton CF; Baliga PK; Chavin KD
    Transpl Infect Dis; 2017 Dec; 19(6):. PubMed ID: 28921781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of cytomegalovirus (CMV) hyperimmune globulin for prevention of CMV disease in CMV-seropositive lung transplant recipients.
    Zamora MR; Fullerton DA; Campbell DN; Leone S; Diercks MJ; Fisher JH; Badesch DB; Grover FL
    Transplant Proc; 1994 Oct; 26(5 Suppl 1):49-51. PubMed ID: 7940974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term results of CMV hyperimmune globulin prophylaxis in 377 heart transplant recipients.
    Kocher AA; Bonaros N; Dunkler D; Ehrlich M; Schlechta B; Zweytick B; Grimm M; Zuckermann A; Wolner E; Laufer G
    J Heart Lung Transplant; 2003 Mar; 22(3):250-7. PubMed ID: 12633691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Specific anti-cytomegalovirus immunoglobulins in the prevention of cytomegalovirus infections in bone marrow allografts].
    Huart JJ; Baume D; Jouet JP
    Ann Med Interne (Paris); 1987; 138(5):372-4. PubMed ID: 2823667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients.
    Snydman DR; Werner BG; Heinze-Lacey B; Berardi VP; Tilney NL; Kirkman RL; Milford EL; Cho SI; Bush HL; Levey AS
    N Engl J Med; 1987 Oct; 317(17):1049-54. PubMed ID: 2821397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytomegalovirus prophylaxis and treatment following bone marrow transplantation.
    Tsinontides AC; Bechtel TP
    Ann Pharmacother; 1996 Nov; 30(11):1277-90. PubMed ID: 8913411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytomegalovirus immune globulin (CMVIG) prophylaxis is associated with increased survival after orthotopic liver transplantation. The Boston Center for Liver Transplantation CMVIG Study Group.
    Falagas ME; Snydman DR; Ruthazer R; Griffith J; Werner BG; Freeman R; Rohrer R
    Clin Transplant; 1997 Oct; 11(5 Pt 1):432-7. PubMed ID: 9361936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Studies evaluating high-dose acyclovir, intravenous immune globulin, and cytomegalovirus hyperimmunoglobulin for prophylaxis against cytomegalovirus in kidney transplant recipients.
    Dickinson BI; Gora-Harper ML; McCraney SA; Gosland M
    Ann Pharmacother; 1996 Dec; 30(12):1452-64. PubMed ID: 8968459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of cytomegalovirus infection by prophylaxis with an intravenous, hyperimmune, native, unmodified cytomegalovirus globulin. Randomized trial in bone marrow transplant recipients.
    Condie RM; O'Reilly RJ
    Am J Med; 1984 Mar; 76(3A):134-41. PubMed ID: 6324587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cytomegalovirus hyperimmune globulin prophylaxis in bone marrow transplants in children with various diseases].
    Ebell W; Blütters-Sawatzki R; Friedrich W; Hampl W; Kleihauer E
    Immun Infekt; 1985 Nov; 13(6):307-12. PubMed ID: 3000925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical and biological evaluation of the preventive role of anti-cytomegalovirus specific immunoglobulins in bone marrow grafts. Randomized study of 60 patients].
    Bordigoni P; Janot C; Aymard JP; Witz F; Bené MC; Legras B; Schoonemann F; Olive D; Streiff F
    Nouv Rev Fr Hematol (1978); 1987; 29(5):289-93. PubMed ID: 2830588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Historical overview of the use of cytomegalovirus hyperimmune globulin in organ transplantation.
    Snydman DR
    Transpl Infect Dis; 2001; 3 Suppl 2():6-13. PubMed ID: 11926753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Risk factors for the occurrence of pneumonia caused by cytomegaloviruses in patients with bone marrow transplants during prevention with cytomegalovirus hyperimmune globulin].
    Schmeiser T; Heit W
    Immun Infekt; 1985 Nov; 13(6):302-6. PubMed ID: 3000924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of cytomegalovirus-related death by passive immunization. A double-blind placebo-controlled study in kidney transplant recipients treated for rejection.
    Metselaar HJ; Rothbarth PH; Brouwer RM; Wenting GJ; Jeekel J; Weimar W
    Transplantation; 1989 Aug; 48(2):264-6. PubMed ID: 2547256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized prospective controlled trial of oral acyclovir versus oral ganciclovir for cytomegalovirus prophylaxis in high-risk kidney transplant recipients.
    Flechner SM; Avery RK; Fisher R; Mastroianni BA; Papajcik DA; O'Malley KJ; Goormastic M; Goldfarb DA; Modlin CS; Novick AC
    Transplantation; 1998 Dec; 66(12):1682-8. PubMed ID: 9884259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical use of immunoglobulin titers of anti-cytomegalovirus antibodies].
    Pouteil-Noble C; Touraine JL; Gibert R; Aymard M
    Rev Fr Transfus Immunohematol; 1984 Jun; 27(3):365-74. PubMed ID: 6091228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytomegalovirus Immunoglobulin After Thoracic Transplantation: An Overview.
    Grossi P; Mohacsi P; Szabolcs Z; Potena L
    Transplantation; 2016 Mar; 100 Suppl 3(Suppl 3):S1-4. PubMed ID: 26900989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.